JP7675716B2 - ３’－ｒｎａオリゴヌクレオチドの合成 - Google Patents

３’－ｒｎａオリゴヌクレオチドの合成 Download PDF

Info

Publication number
JP7675716B2
JP7675716B2 JP2022530757A JP2022530757A JP7675716B2 JP 7675716 B2 JP7675716 B2 JP 7675716B2 JP 2022530757 A JP2022530757 A JP 2022530757A JP 2022530757 A JP2022530757 A JP 2022530757A JP 7675716 B2 JP7675716 B2 JP 7675716B2
Authority
JP
Japan
Prior art keywords
base
uracil
nucleoside
alkyl
group
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2022530757A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023503985A5 (https=
JP2023503985A (ja
Inventor
ケー ナイル，ジャヤプラカーシュ
シー サリナス，ジュアン
フレデリック ブリオネス，ジョン
ケー シュレーゲル，マルク
マツダ，シゲオ
ヴィ ケリン，アレクサンダー
ヂャン，リーガン
エー マイアー，マーティン
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Alnylam Pharmaceuticals Inc
Original Assignee
Alnylam Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Alnylam Pharmaceuticals Inc filed Critical Alnylam Pharmaceuticals Inc
Publication of JP2023503985A publication Critical patent/JP2023503985A/ja
Publication of JP2023503985A5 publication Critical patent/JP2023503985A5/ja
Priority to JP2025074104A priority Critical patent/JP2025105841A/ja
Application granted granted Critical
Publication of JP7675716B2 publication Critical patent/JP7675716B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H1/00—Processes for the preparation of sugar derivatives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/06—Pyrimidine radicals
    • C07H19/067—Pyrimidine radicals with ribosyl as the saccharide radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
    • C07H21/02—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids with ribosyl as saccharide radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H23/00—Compounds containing boron, silicon or a metal, e.g. chelates or vitamin B12
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/111—General methods applicable to biologically active non-coding nucleic acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering nucleic acids [NA]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/319—Chemical structure of the backbone linked by 2'-5' linkages, i.e. having a free 3'-position
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2330/00—Production
    • C12N2330/30—Production chemically synthesised
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biophysics (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Dispersion Chemistry (AREA)
  • Dermatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Saccharide Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
JP2022530757A 2019-11-27 2020-11-23 ３’－ｒｎａオリゴヌクレオチドの合成 Active JP7675716B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2025074104A JP2025105841A (ja) 2019-11-27 2025-04-28 ３’－ｒｎａオリゴヌクレオチドの合成

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962941153P 2019-11-27 2019-11-27
US62/941,153 2019-11-27
PCT/US2020/061755 WO2021108291A1 (en) 2019-11-27 2020-11-23 Synthesis of 3'-rna oligonucleotides

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2025074104A Division JP2025105841A (ja) 2019-11-27 2025-04-28 ３’－ｒｎａオリゴヌクレオチドの合成

Publications (3)

Publication Number Publication Date
JP2023503985A JP2023503985A (ja) 2023-02-01
JP2023503985A5 JP2023503985A5 (https=) 2023-10-03
JP7675716B2 true JP7675716B2 (ja) 2025-05-13

Family

ID=76129612

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2022530757A Active JP7675716B2 (ja) 2019-11-27 2020-11-23 ３’－ｒｎａオリゴヌクレオチドの合成
JP2025074104A Pending JP2025105841A (ja) 2019-11-27 2025-04-28 ３’－ｒｎａオリゴヌクレオチドの合成

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2025074104A Pending JP2025105841A (ja) 2019-11-27 2025-04-28 ３’－ｒｎａオリゴヌクレオチドの合成

Country Status (10)

Country Link
US (1) US20250325575A2 (https=)
EP (1) EP4065715A4 (https=)
JP (2) JP7675716B2 (https=)
KR (1) KR20220107246A (https=)
CN (2) CN118791543A (https=)
AU (1) AU2020391116A1 (https=)
CA (1) CA3162717A1 (https=)
IL (2) IL293327B2 (https=)
MX (1) MX2022006221A (https=)
WO (1) WO2021108291A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2026085164A2 (en) 2024-10-16 2026-04-23 Alnylam Pharmaceuticals, Inc. Snca irna formulations and methods of use thereof

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012024776A1 (en) 2010-08-23 2012-03-01 The Royal Institution For The Advancement Of Learning/Mcgill University Block synthesis of oligoribonucleotides
US20130261026A1 (en) 2001-03-14 2013-10-03 The Regents Of The University Of Michigan Linkers and co-coupling agents for optimization of oligonucleotide synthesis and purification on solid supports

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4924624A (en) * 1987-10-22 1990-05-15 Temple University-Of The Commonwealth System Of Higher Education 2,',5'-phosphorothioate oligoadenylates and plant antiviral uses thereof
ATE299509T1 (de) * 1992-07-23 2005-07-15 Isis Pharmaceuticals Inc Neue 2'-o-alkyl-nukleoside und -phosphoramidite, verfahren zu ihrer herstellung und ihre verwendungen
US6649750B1 (en) * 2000-01-05 2003-11-18 Isis Pharmaceuticals, Inc. Process for the preparation of oligonucleotide compounds
WO2002018405A2 (en) * 2000-09-01 2002-03-07 Ribozyme Pharmaceuticals, Incorporated Methods for synthesizing nucleosides, nucleoside derivatives and non-nucleoside derivatives
WO2003039523A2 (en) * 2001-11-05 2003-05-15 Exiqon A/S OLIGONUCLEOTIDES MODIFIED WITH NOVEL α-L-RNA ANALOGUES
CN100484949C (zh) * 2005-07-18 2009-05-06 张必良 用于rna寡核苷酸合成中的核苷亚磷酰胺及其合成方法
US8911948B2 (en) * 2008-04-30 2014-12-16 Integrated Dna Technologies, Inc. RNase H-based assays utilizing modified RNA monomers
US8309707B2 (en) * 2008-09-06 2012-11-13 Chemgenes Corporation RNA synthesis-phosphoramidites for synthetic RNA in the reverse direction, and application in convenient introduction of ligands, chromophores and modifications of synthetic RNA at the 3′-end
US8541569B2 (en) * 2008-09-06 2013-09-24 Chemgenes Corporation Phosphoramidites for synthetic RNA in the reverse direction, efficient RNA synthesis and convenient introduction of 3'-end ligands, chromophores and modifications of synthetic RNA
CA2900238A1 (en) * 2013-02-22 2014-08-28 Sirna Therapeutics, Inc. Short interfering nucleic acid (sina) molecules containing a 2' internucleoside linkage
EP3154996B1 (en) * 2014-06-10 2020-03-11 Agilent Technologies, Inc. Protecting groups for "z nucleotide" and methods thereof
EP3455232B1 (en) * 2016-05-12 2020-05-06 Roche Innovation Center Copenhagen A/S Enhanced coupling of stereodefined oxazaphospholidine phosphoramidite monomers to nucleoside or oligonucleotide
WO2018019748A1 (en) * 2016-07-27 2018-02-01 F. Hoffmann-La Roche Ag 5's-lna nucleotides and oligonucleotides

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20130261026A1 (en) 2001-03-14 2013-10-03 The Regents Of The University Of Michigan Linkers and co-coupling agents for optimization of oligonucleotide synthesis and purification on solid supports
WO2012024776A1 (en) 2010-08-23 2012-03-01 The Royal Institution For The Advancement Of Learning/Mcgill University Block synthesis of oligoribonucleotides

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
Bioconjugate Chemistry，2003年，Vol. 14，pp. 690-696
GREENE, Theodora W. et al.，Protective Groups in Organic Synthesis, Third Edition，1999年04月09日，pp. 123-125
Helvetica Chimica Acta，2003年，Vol. 86，pp. 2726-2740
Journal of Sciences, Islamic Republic of Iran，1990年，Vol. 1，pp. 355-360
The Journal of Organic Chemistry，1990年，Vol. 55，pp. 4717-4724
Triisopropylsilyl Chloride，Encyclopedia of Reagents for Organic Synthesis，2001年，pp. 1-5，10.1002/047084289X.rt262

Also Published As

Publication number Publication date
WO2021108291A1 (en) 2021-06-03
IL293327B2 (en) 2026-04-01
EP4065715A1 (en) 2022-10-05
CA3162717A1 (en) 2021-06-03
IL324170A (en) 2025-12-01
US20230021879A1 (en) 2023-01-26
EP4065715A4 (en) 2024-04-10
CN115038790B (zh) 2024-06-21
IL293327B1 (en) 2025-12-01
MX2022006221A (es) 2022-08-10
CN118791543A (zh) 2024-10-18
IL293327A (en) 2022-07-01
JP2023503985A (ja) 2023-02-01
AU2020391116A1 (en) 2022-07-14
JP2025105841A (ja) 2025-07-10
US20250325575A2 (en) 2025-10-23
KR20220107246A (ko) 2022-08-02
CN115038790A (zh) 2022-09-09

Similar Documents

Publication Publication Date Title
JP4402454B2 (ja) Ｌｎａホスホラミダイトの製造法
JP5157168B2 (ja) ホスホロアミダイト化合物及びオリゴｒｎａの製法
JP4476802B2 (ja) ロックト核酸誘導体の製造
US7569575B2 (en) Synthesis of locked nucleic acid derivatives
JP5187189B2 (ja) 核酸保護基の脱離方法
JP2025105841A (ja) ３’－ｒｎａオリゴヌクレオチドの合成
JP2024054157A (ja) 修飾ヌクレオシドホスホロアミダイト
JP2019508438A (ja) 核配列に組み込むための５−（ｎ−保護−トリプタミノカルボキシアミド）−２’−デオキシウリジンホスホロアミダイトの化合物及び合成方法
JPWO2007097446A1 (ja) オリゴ核酸のキャッピング法
JPWO2007097447A1 (ja) 核酸保護基の脱離方法
CN101522701B (zh) 核酸保护基的导入方法
KR20240082343A (ko) 정제 디클로로아세트산의 제조 방법
US7820810B2 (en) Process for the synthesis of 2′-O-substituted purine nulceosides
JP2022177332A (ja) オリゴヌクレオチドを製造する方法
WO2006095739A1 (ja) リボヌクレオシドの２’水酸基の脱保護方法
BR112020005067B1 (pt) Fosforamiditas nucleosídeo modificadas, composição, e métodos para produzir um oligonucleotídeo
EA045540B1 (ru) Модифицированные нуклеозидные амидофосфиты

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220704

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230925

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20230925

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20240912

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20241211

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20250401

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20250428

R150 Certificate of patent or registration of utility model

Ref document number: 7675716

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150